These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22669600)

  • 1. Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab.
    Fusama M; Nakahara H; Hamano Y; Nishide M; Kawamoto K; Hosokawa T; Nozato S; Higa S; Igarashi T; Takeuchi E; Kuroiwa T; Shimaoka Y; Yukioka M; Miura Y; Higashi K; Kuritani T; Maeda K
    Mod Rheumatol; 2013 Mar; 23(2):276-83. PubMed ID: 22669600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
    Kawashiri SY; Nishino A; Suzuki T; Nakashima Y; Horai Y; Ueki Y; Aramaki T; Fujikawa K; Nakashima M; Okada A; Migita K; Mizokami A; Matsuoka N; Mine M; Sakito S; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aoyagi K; Eguchi K; Kawakami A
    Clin Exp Rheumatol; 2016; 34(5):808-812. PubMed ID: 27384149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
    Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
    Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tocilizumab on MRI-determined bone oedema in rheumatoid arthritis.
    Bensaoud N; Rostom S; Bahiri R; Hajjaj-Hassouni N
    Clin Rheumatol; 2015 Jun; 34(6):1031-7. PubMed ID: 25903819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study.
    Wakabayashi H; Hasegawa M; Nishioka Y; Sudo A; Nishioka K
    Mod Rheumatol; 2012 Feb; 22(1):116-21. PubMed ID: 21710357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components.
    Bastida C; Soy D; Ruiz-Esquide V; Sanmartí R; Huitema ADR
    Br J Clin Pharmacol; 2019 Aug; 85(8):1710-1718. PubMed ID: 30958574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
    Yazici Y; Curtis JR; Ince A; Baraf H; Malamet RL; Teng LL; Kavanaugh A
    Ann Rheum Dis; 2012 Feb; 71(2):198-205. PubMed ID: 21949007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts.
    Matsuno H
    Mod Rheumatol; 2015 Jan; 25(1):38-42. PubMed ID: 25529071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Origuchi T; Ueki Y; Migita K; Mizokami A; Aoyagi K; Eguchi K
    Mod Rheumatol; 2011 Aug; 21(4):370-4. PubMed ID: 21240618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept.
    Hirota T; Suzuki T; Ogishima H; Hagiwara S; Ebe H; Takahashi H; Yokosawa M; Umeda N; Kondo Y; Tsuboi H; Matsumoto I; Sumida T
    Mod Rheumatol; 2016; 26(1):29-35. PubMed ID: 26140463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.
    Akiyama M; Kaneko Y; Yamaoka K; Kondo H; Takeuchi T
    Rheumatol Int; 2016 Jun; 36(6):881-9. PubMed ID: 27072347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study.
    Terenzi R; Santoboni G; Bartoloni E; Alunno A; Luccioli F; Gerli R
    Clin Exp Rheumatol; 2015; 33(3):445. PubMed ID: 25937244
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.